{"nctId":"NCT04171414","briefTitle":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","startDateStruct":{"date":"2019-09-09","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":62,"armGroups":[{"label":"\"CT-P17 SC AI (adalimumab)\"","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P17 SC AI (adalimumab)"]}],"interventions":[{"name":"CT-P17 SC AI (adalimumab)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patient aged 18 to 70 years, inclusive.\n* Patient must be able and willing to self-administer subcutaneous (SC) injections via auto injector (AI).\n\nExclusion Criteria:\n\n* Patient who has previously received investigational or licensed product; biologic or targeted synthetic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis and/or a tumor necrosis factor (TNF) Î± inhibitor for any purposes.\n* Patient who has allergies to any of the excipients of study drug or any other murine and human proteins, or patient with a hypersensitivity to immunoglobulin products.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4","description":"The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). \\[Scores were transformed to Rate between 0 (worst) to 10 (best)\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.00","spread":"2.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.16","spread":"2.036"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.55","spread":"1.859"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":"1.616"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.39","spread":"2.079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.59","spread":"0.968"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.70","spread":"1.457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.27","spread":"1.669"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":"1.191"}]}]}]},{"type":"SECONDARY","title":"Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":"2.437"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.04","spread":"2.086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.22","spread":"2.272"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.18","spread":"2.518"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.35","spread":"2.306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.48","spread":"1.152"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.40","spread":"1.531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.15","spread":"1.682"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.00","spread":"1.250"}]}]}]},{"type":"SECONDARY","title":"Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)","description":"DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.\n\nDAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity.\n\nAbbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.248","spread":"0.8415"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.560","spread":"1.1223"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.795","spread":"1.2381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.111","spread":"1.1109"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.190","spread":"0.7360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.287","spread":"1.3525"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.495","spread":"1.4695"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.799","spread":"1.4287"}]}]}]},{"type":"SECONDARY","title":"Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":"2.175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.08","spread":"2.110"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":"2.007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"1.811"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.27","spread":"2.245"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.64","spread":"0.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.34","spread":"1.698"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.78","spread":"2.128"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.16","spread":"1.177"}]}]}]},{"type":"SECONDARY","title":"Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.88","spread":"2.034"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"1.888"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.21","spread":"1.556"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.44","spread":"1.840"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.04","spread":"1.533"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.60","spread":"0.841"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.35","spread":"1.057"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.83","spread":"1.868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.95","spread":"1.023"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":62},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Diarrhoea","Headache","Hyperbilirubinaemia"]}}}